These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 9917092

  • 1. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P, Zheng C, Moyana T, Xiang J.
    Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
    [Abstract] [Full Text] [Related]

  • 2. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J, Chen Y, Moyana T.
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
    Xiang J, Qi Y, Chen Y.
    Cancer Gene Ther; 1997 Jul; 4(6):353-8. PubMed ID: 9408605
    [Abstract] [Full Text] [Related]

  • 4. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-tau.
    Qi Y, Moyana T, Chen Y, Xiang J.
    Hum Antibodies Hybridomas; 1996 Jul; 7(1):21-6. PubMed ID: 8886833
    [Abstract] [Full Text] [Related]

  • 5. Antitumor vaccination with gene-transduced tumor cells expressing a fusion protein RM4/IFN-tau.
    Xiang J.
    Cancer Biother Radiopharm; 1997 Apr; 12(2):123-30. PubMed ID: 10851456
    [Abstract] [Full Text] [Related]

  • 6. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells.
    Xiang J, Qi Y, Cook D, Moyana T.
    Hum Antibodies Hybridomas; 1996 Aug; 7(1):2-10. PubMed ID: 8886831
    [Abstract] [Full Text] [Related]

  • 9. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R, Xing Z, Xiang J.
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [Abstract] [Full Text] [Related]

  • 10. Mouse myeloma cell line secreting bifunctional fusion protein RM4/IFN-gamma [corrected] elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Qi Y, Chen Y, Xiang J.
    J Interferon Cytokine Res; 1996 Oct; 16(10):771-6. PubMed ID: 8910761
    [Abstract] [Full Text] [Related]

  • 11. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W, Yang H, Wang Z, Jim X.
    Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
    [Abstract] [Full Text] [Related]

  • 12. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
    Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, Entwisle C, Blakeley DM, Shields JG, Todryk S, Vile R, Robins RA, Rees RC.
    Cancer Res; 2000 Mar 15; 60(6):1663-70. PubMed ID: 10749137
    [Abstract] [Full Text] [Related]

  • 13. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF, Berger AC, Huang J, Puhlmann M, Wu PC, Merino MJ, Bartlett DL, Alexander HR, Libutti SK.
    Cancer Res; 1999 Sep 15; 59(18):4668-74. PubMed ID: 10493523
    [Abstract] [Full Text] [Related]

  • 14. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z, Shi M, Chan T, Sas S, Xu S, Xiang J.
    Cancer Gene Ther; 2007 Jul 15; 14(7):661-75. PubMed ID: 17479109
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U, Benhar I, Webber KO, Pastan I, Brinkmann U.
    Clin Cancer Res; 1996 Sep 15; 2(9):1523-31. PubMed ID: 9816329
    [Abstract] [Full Text] [Related]

  • 18. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 15; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
    Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B.
    Cancer Res; 2001 Apr 15; 61(8):3330-8. PubMed ID: 11309289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.